Interaction network linking the human H3N2 influenza A virus genomic RNA segments.

Abstract : The genome of influenza A viruses is comprised of eight negative-sense viral RNAs (vRNAs) that form viral ribonucleoproteins (vRNPs). In order to be infectious, an influenza A viral particle must encapsidate at least one copy of each of the vRNAs. Thus, even though genome segmentation is evolutionary advantageous, it undeniably complicates viral assembly, which is believed to occur through a selective mechanism that still remains to be understood. Using electron tomography 3D-reconstructions, we show that the eight vRNPs of an influenza A Moscow/10/99 (H3N2) virus are interconnected within a star-like structure as they emerge from a unique "transition zone" at the budding tip of the virions. Notably, this "transition zone" is thick enough to accommodate all described packaging signals. We also report that, in vitro, each vRNA segment is involved in a direct contact with at least one other vRNA partner, in a single network of intermolecular interactions. We show that in several cases, the regions involved in vRNA/vRNA interactions overlap with previously identified packaging signals. Our results thus provide support for the involvement of RNA/RNA interactions in the selection and specific packaging of influenza A genomic RNAs, which appear embedded into an organised supramolecular complex likely held together by direct base-pairings between packaging signals.
Type de document :
Article dans une revue
Vaccine, Elsevier, 2012, 30 (51), pp.7359-67. 〈10.1016/j.vaccine.2012.09.079〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00870438
Contributeur : Morgane Le Corre <>
Soumis le : lundi 7 octobre 2013 - 12:01:59
Dernière modification le : vendredi 30 mars 2018 - 18:12:02

Identifiants

Citation

Emilie Fournier, Vincent Moules, Boris Essere, Jean-Christophe Paillart, Jean-Daniel Sirbat, et al.. Interaction network linking the human H3N2 influenza A virus genomic RNA segments.. Vaccine, Elsevier, 2012, 30 (51), pp.7359-67. 〈10.1016/j.vaccine.2012.09.079〉. 〈inserm-00870438〉

Partager

Métriques

Consultations de la notice

151